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Parsippany, NJ, USA
OBJECTIVES: To compare hypoglycemia event rates and the
associated cost-consequence in patients initiated on long-acting
analogue insulin (glargine) or intermediate-acting insulins
(NPH). METHODS: This was a longitudinal administrative
claims database analysis from a managed care perspective using
a retrospective cohort design. Data were obtained from a large
southeastern US managed care plan with approximately 2.5
million quality data lives. All patients newly initiated on glargine
or NPH between July 1, 2000 and August 31, 2002 were iden-
tiﬁed (no use of glargine/NPH in the 4 months prior to index
date). Hypoglycemia event rates were identiﬁed by the presence
of medical claims with ICD-9-CM codes. Analyses were per-
formed using multivariable regression techniques. RESULTS:
The sample size was 1434 patients (glargine = 310, NPH =
1124). Mean age was 53 ± 17 years; 51.5% were male. Mean
treatment duration was 9 ± 4 months. After controlling for A1C
and other cogent demographic and clinical variables, patients in
the NPH cohort had a higher hypoglycemia event rate than the
glargine group (18.3 versus 7.3 per 100 patients/year; p = 0.009).
This event rate yielded a number-needed-to-treat of nine patients
(glargine versus NPH) to avoid one hypoglycemia event per
member per year (PMPY). Mean cost per hypoglycemia event
was $1087 (95% CI: $764–$1409). Mean annual index 
medication costs for the glargine cohort were $47 more PMPY
compared to the NPH cohort ($390 versus $343; p =
0.042). CONCLUSIONS: Patients treated with glargine had a
lower hypoglycemia event rate compared to NPH. The increased
cost associated with treating nine patients with glargine for 
one year (i.e., 9 ¥ $47 = $423) is less than the cost to treat one
hypoglycemic event ($1087).
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ESTIMATING THE REDUCTION IN LONG TERM
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DIABETES BY REDUCED A1C LEVELS DUE TO MORE
FREQUENT BLOOD GLUCOSE MONITORING
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OBJECTIVES: To simulate the impact of increased daily blood
glucose monitoring on risk of late complications for Type-1dia-
betes patients. METHODS: Previous studies have shown a rela-
tionship between increased daily blood glucose monitoring
(BGM) and reduced A1C levels for Type-1 diabetes patients. This
analysis quantiﬁes the reduced risk for complications and esti-
mates the lifetime costs for complications by modeling the effects
of BGM induced lower A1C levels over a lifetime. A standard
Monte Carlo simulation combining published literature for risk
of long-term diabetic complications with risk functions for each
complication was used. Clinical outcomes were based upon 
following diabetic complications: cardiovascular, neuropathy,
nephropathy, retinopathy, keto-and lacto acidosis and hypo-
glycemia. Lifetime costs for complications were calculated as the
yearly costs treating the different complications (US Medicare
perspective) over a 50-year period. Clinical outcomes and life-
time costs were discounted at 3%. Patient baseline data were
taken from a representative cohort of newly diagnosed type-1
diabetes patients. The effect of testing BG on A1C was taken
from published literature, which showed that the reduction in
A1C values from baseline was 0.70% (p < 0.001) by having one
daily BGM. Other studies have found similar reductions.
RESULTS: The difference in QALY was 0.46 years (LYG was
0.37 years) and lifetime cost was lower, due to fewer complica-
tions for the group with more frequent BGM ($54,800 vs.
$60,900 per patient over time). Furthermore, clinical outcomes
showed that the largest difference in reduced risk for complica-
tions was for nephropathy where the risk was reduced by more
than half in the group which did more BG test. Sensitivity analy-
ses support the validity and reliability of the results. CONCLU-
SIONS: This study showed the importance of BG testing on the
risk of complications for Type 1 diabetes patients. The reduced
risk for complications translates into less costs and thus less
burden for the patients and the society.
PDB13
PHARMACY AND MEDICAL RESOURCE UTILIZATION AMONG
INITIAL METFORMIN AND THIAZOLIDINEDIONE PATIENTS
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OBJECTIVE: To compare prescription and medical resource 
utilization by patients in Maryland Medicaid plans who are 
initiated on thiazolidinediones (TZDs) versus those initiated on
metformin. METHODS: This study includes a prospective non-
concurrent analysis of prescription and medical claims for Mary-
land Medicaid patients who were initiated on metformin or
TZDs between June 15, 2000 and June 15, 2002. We ran uni-
variate, bivariate, and multivariate models, examining the asso-
ciations between the likelihood of being initiated on a TZD and
age, gender, race, county of residence, coverage group, and days
supply, as well as variables to assess resource utilization: drug
count, total pharmacy claims, unique diagnoses count, and total
medical claims. Logistic regression models were used to assess
the combined effect of all utilization variables on the likelihood
of incident use of TZDs or metformin, adjusting for demo-
graphic variables. We also tracked the use of metformin and
TZDs in this population. RESULTS: The sample of 4440 patients
was mostly female (71.19%), older (52.58% over 49 years old)
and African American (58.84%). Patients with higher numbers
of unique diagnoses (OR = 1.6, p = 0.0071), prescription claims
(OR = 1.5, p = 0.0813), and unique drugs (OR = 1.7, p = 0.028)
were more likely to have received TZDs ﬁrst line. Those patients
with higher numbers of medical claims (OR = 0.5, p = 0.0029)
were less likely to have been started on TZDs. Among patients
started on metformin, 84% did not have subsequent use of
TZDs. Among those started on TZDs, 82% did not use 
metformin. CONCLUSIONS: Results show that patients initi-
ated on TZDs are more likely to have subsequently higher uti-
lization of prescription resources, even after adjusting for
demographic variables. These patients were also likely to use less
medical resources than metformin initial users.
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OBJECTIVE: To compare results from two approaches—
propensity score binning or matching—for reduction of selection
